PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 21, 2024Circulation37 citationsOpen Access

A Latent Cardiomyocyte Regeneration Potential in Human Heart Disease

View Full Paper
WDWouter DerksJRJulian RodeSCSofia Collin

Key Result

Patients with advanced heart failure receiving left ventricular assist device therapy who showed functional improvement had a cardiomyocyte renewal rate of 3.1% per year, a >6-fold increase relative to healthy hearts.

Study Design

Type

Observational (n=52)

Multicenter

Yes

Structured PICO

Does left ventricular assist device (LVAD) support increase cardiomyocyte renewal in patients with advanced heart failure?

P
Population
52 patients aged 18 to 68 years with advanced heart failure, including 28 who received left ventricular assist device support, evaluated for cardiomyocyte renewal.
E
Exposure
Left ventricular assist device (LVAD) support (n=28)
C
Comparator
Advanced heart failure without LVAD unloading (n=24) and healthy heart reference
O
Outcome
Cardiomyocyte renewal rate (measured via nuclear bomb test-derived 14C in cardiomyocyte genomic DNA)surrogate

LVAD unloading in advanced heart failure unmasks a latent potential for cardiomyocyte regeneration, significantly increasing renewal rates.

Main Result

Absolute Event Rate: 3.1% vs 0.03%

Limitations

  • Retrospective study design
  • Difficulty in establishing exact causal relationship between reverse remodeling, functional improvement, and cardiomyocyte renewal
  • Reliance on mathematical modeling to estimate renewal rates

Abstract

BACKGROUND: Cardiomyocytes in the adult human heart show a regenerative capacity, with an annual renewal rate of ≈0.5%. Whether this regenerative capacity of human cardiomyocytes is employed in heart failure has been controversial. METHODS: We determined cardiomyocyte renewal in 52 patients with advanced heart failure, 28 of whom received left ventricular assist device support. We measured the concentration of nuclear bomb test–derived 14 C in cardiomyocyte genomic DNA and performed mathematical modeling to establish cardiomyocyte renewal in heart failure with and without LVAD unloading. RESULTS: We show that cardiomyocyte generation is minimal in end-stage heart failure patients at rates 18 to 50× lower compared with the healthy heart. However, patients receiving left ventricle support device therapy, who showed significant functional and structural cardiac improvement, had a >6-fold increase in cardiomyocyte renewal relative to the healthy heart. CONCLUSIONS: Our findings reveal a substantial cardiomyocyte regeneration potential in human heart disease, which could be exploited therapeutically.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Derks et al. (2024) conducted an observational in Advanced heart failure (n=52). Left ventricular assist device (LVAD) support vs. Non-LVAD advanced heart failure was evaluated on Annual cardiomyocyte renewal rate. Patients with advanced heart failure receiving left ventricular assist device therapy who showed functional improvement had a cardiomyocyte renewal rate of 3.1% per year, a >6-fold increase relative to healthy hearts.

synapsesocial.com/papers/6aa72b1d3a3f92caa71b3336https://doi.org/10.1161/circulationaha.123.067156
Ask AI
Helpful
Bookmark
Share
View Full Paper